The objective response rate (ORR) of anti-PD-1 monotherapy reported in inoperable stage III/IV melanoma is around 42–45%, while ORR reported in chemotherapy-refractory metastatic urothelial cancer is considerably lower (15–28.6%) [24,25,26,27]. Here, PDCD1 is linked to melanoma.